Susan Molineaux, Calithera CEO (via Lightstone Ventures)

Still reel­ing from PhII fail­ure, Calithera beefs up its on­col­o­gy port­fo­lio with a lit­tle help from Take­da

Calithera start­ed the year by ax­ing a third of its staff af­ter a mon­u­men­tal Phase II flop in re­nal cell car­ci­no­ma. And while CEO …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.